Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trial

Autor: L Peyrin-Biroulet, S Vermeire, G R D’Haens, J Panés, A Dignass, F Magro, M Le Bars, M Lahaye, M Nazar, L Ni, I Bravatà, F Lavie, M Daperno, M Lukáš, A Armuzzi, M Löwenberg, D R Gaya, S Danese

Publikováno v: Journal of Crohn's and Colitis. 16:i132-i134

Background STARDUST is a phase 3b randomized trial comparing two therapeutic strategies with ustekinumab (UST) in patients (pts) with Crohn’s disease (CD): treat-to-target (T2T) using early endoscopic assessment vs standard of care (SoC). Results f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c25e07d580c0eb78af27b0d10cb1bd1
https://doi.org/10.1093/ecco-jcc/jjab232.129

Zobrazit plný text záznamu

POS0072 CONSISTENT LONG-TERM GUSELKUMAB EFFICACY ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE PATIENT CHARACTERISTICS

Autor: I. Mcinnes, J. Tesser, E. Schiopu, J. F. Merola, S. D. Chakravarty, E. Rampakakis, N. Shiff, A. Kollmeier, X. L. Xu, M. Shawi, F. Lavie, P. Bird, P. J. Mease

Publikováno v: Annals of the Rheumatic Diseases. 81:253-254

BackgroundPsoriatic arthritis (PsA) patients (pts) with differing baseline (BL) characteristics may vary in their response to treatment. In the phase 3 DISCOVER-1 and DISCOVER-2 studies, guselkumab (GUS) significantly improved joint symptoms, skin di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69b8b0220822b2ee4b068cb66e474800
https://doi.org/10.1136/annrheumdis-2022-eular.47

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

POS1035 LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23p19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Autor: P. J. Mease, A. B. Gottlieb, I. Mcinnes, P. Rahman, A. Kollmeier, X. L. Xu, Y. Jiang, S. Sheng, M. Shawi, S. D. Chakravarty, F. Lavie, D. Van der Heijde

Publikováno v: Annals of the Rheumatic Diseases. 81:831.2-832

BackgroundIn the phase 3 DISCOVER-2 (D2) study, guselkumab (GUS) 100 mg every 4/8 weeks (Q4W/Q8W) significantly improved joint and skin symptoms in patients (pts) with active psoriatic arthritis (PsA); GUS-treated pts had smaller mean changes in radi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5f00cd9e80d4e43c265bc542c5daa6f9
https://doi.org/10.1136/annrheumdis-2022-eular.1508

Zobrazit plný text záznamu

POS1031 EARLIER CLINICAL RESPONSE PREDICT LOW RATES OF RADIOGRAPHIC PROGRESSION IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT

Autor: P. J. Mease, A. B. Gottlieb, A. Ogdie, I. Mcinnes, S. D. Chakravarty, E. Rampakakis, A. Kollmeier, X. L. Xu, M. Shawi, F. Lavie, M. Kishimoto, P. Rahman

Publikováno v: Annals of the Rheumatic Diseases. 81:828.2-829

BackgroundGuselkumab (GUS), an IL-23p19-subunit inhibitor, demonstrated efficacy and a favorable safety profile in patients (pts) with psoriasis (PsO) and psoriatic arthritis (PsA). In the Phase 3, double-blind, placebo (PBO)-controlled DISCOVER-2 st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2785f4a0e5ab1b8d6904c97b9264cf82
https://doi.org/10.1136/annrheumdis-2022-eular.1386

Zobrazit plný text záznamu

POS0308 EFFECT OF GUSELKUMAB ON SERUM BIOMARKERS IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE COSMOS STUDY

Autor: G. Schett, W. Chen, S. Gao, S. D. Chakravarty, M. Shawi, F. Lavie, E. Theander, M. Neuhold, L. Coates, S. Siebert

Publikováno v: Annals of the Rheumatic Diseases. 81:403.2-404

BackgroundGuselkumab (GUS), a selective IL-23 inhibitor, is efficacious in treating bio-naïve and TNFi-experienced active PsA patients (pts).1.2 In the COSMOS study of active PsA pts with lack of efficacy/intolerance, i.e., inadequate response (IR),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42db25232fc5a61b9b03493d0532af76
https://doi.org/10.1136/annrheumdis-2022-eular.736

Zobrazit plný text záznamu

POS0074 IMMUNOLOGICAL DIFFERENCES BETWEEN PsA PATIENTS WHO ARE TUMOR NECROSIS FACTOR INHIBITOR-NAIVE AND WHO HAVE INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS

Autor: S. Siebert, L. Coates, G. Schett, S. P. Raychaudhuri, W. Chen, S. Gao, S. D. Chakravarty, M. Shawi, F. Lavie, E. Theander, M. Neuhold, A. Kollmeier, X. L. Xu, P. Rahman, P. J. Mease, A. Deodhar

Publikováno v: Annals of the Rheumatic Diseases. 81:254.2-255

BackgroundA better understanding of the immunological differences between psoriatic arthritis (PsA) patients (pts) who are tumor necrosis factor inhibitor (TNFi)-naïve & who have inadequate response to TNFi (TNFi-IR) may guide treatment choices. In

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80dc6d39321d969f7f39389acd3516d7
https://doi.org/10.1136/annrheumdis-2022-eular.892

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání